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and is usually related to specific triggering events, airway narrowing that is partially or completely reversible and increased airways responsiveness to a variety of stimuli. [1] The inflammatory features characteristic of asthma include infiltration of the airway by inflammatory cells, resulting in an increase in airway edema and mucus secretion, hypertrophy and hyperplasia of airway smooth muscle cells and increased airway vulnerability, all of which contribute to airflow obstruction. [2] Asthma is the most common chronic disease in childhood in the first world countries. Data from the CDC-based National Centre for Health Statistics show an increase in asthma prevalence from 1980 to 1996 by greater than 50%. [3] The largest increase was seen in persons younger than 18 years. The CDC's 2003 National
Health Interview Survey yielded a lifetime asthma prevalence of 12.5% and current asthma prevalence of 8.5% among children ≤18 years. [4] Prevalence of asthma was 2.3 and 3.3% in the children of age group 6/7 and 13/14 years, respectively, in Lucknow, North India. [5] Asthma also negatively affects children during critical periods of growth and development, leading to increased annual cost of treating childhood asthma. [6] Introduction Asthma is a chronic, inflammatory lung disease characterized by symptoms of cough, wheezing, dyspnea, and chest tightness, which occur in paroxysms, Table 1 ]. [1] As many as two-thirds of patients with asthma may not attain full control of their asthma. [7] Up to one-third of patients treated with ICSs may not achieve objective improvements in airway function or indices of airway reactivity. [8] Even more number of patients may not respond to leukotriene antagonists. One-third of patients using oral corticosteroids develop osteoporosis; [9] in addition, 3-5% of patients using a 5-lipoxygenase (ALOX-5) inhibitor develop increases in liver function enzymes. [10] A very small percentage of patients with asthma may be at risk of increased mortality with use of long-acting β-agonists. An estimated 70-80% of variability in individual responses to therapy may have a genetic basis. [11] Pharmacogenomics defines the relationship between the variability in genetic code and the variability in responses to pharmacologic interventions. In addition, it offers to individualize treatment by using genetic information to improve drug efficacy and/or prevent side effects. Thus, the identification of genetic variants that identify asthmatic drug response will offer both prognostic assistance in the determination of response to existing therapy and the potential to develop novel pharmacologic agents. While there are a number of examples in which the approach is already in routine clinical usage, exploitation of this approach in asthma is still under development.
Types of Genetic Variability
Single nucleotide polymorphisms (SNPs) are most commonly used to explore the pharmacogenetics of asthma. [12] Other types of DNA variation include deletions or insertions of one or more bases, variable number of tandem repeats (microsatellites) and varying combinations of SNPs and/or variable numbers of tandem repeats on a single chromosome (haplotypes).
Factors Altering Predicted Pharmacogenomic Associations
It was observed that variations in genes having large effects on a pharmacologic response do not Gupta and Awasthi: Pharmacogenomics of pediatric asthma 
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β-2 agonists β-2 agonists are important bronchodilator drugs commonly used in the treatment of asthma. The β-2AR gene is expressed in bronchial smooth muscle cells and induces dilation in response to endogenous catecholamine or exogenous triggers. It is located on chromosome 5q31-32 and is highly polymorphic, [14] with three functionally relevant coding region polymorphisms and Gln-27 alleles in asthmatic children, which makes it difficult to differentiate the effect of a single SNP because both SNPs are transmitted together.
The Ile-164 polymorphism, which is relatively uncommon, results in a substantial decrease in agonist binding affinity and coupling to adenylate cyclase.
Polymorphisms Gly-16 and Glu-27 do not affect receptor binding or coupling, but markedly alter agonist-promoted receptor downregulation and functional desensitization;
Gly-16 enhances this downregulation, whereas Glu-27 protects against it.
Earlier, it was found that homozygous Gly-16 was associated with a more severe asthma phenotype, [14] but this has not been supported by more recent studies. [15] Gly-16 has also been associated with nocturnal asthma [16] and in children it has been reported to be associated with decreased bronchodilator response to an inhaled β-2 agonist. [17] The Glu-27 polymorphism has been reported to be associated with decreased airway reactivity in asthma. [18] The Gln-27 allele, on the other hand, has been associated with elevated IgE levels and an increase in self-reported asthma in children.
Clinical studies have indicated that the Arg/Arg genotype for residue 16 of the β-2AR alters responses to treatment and disease severity in patients with asthma. Results from one study showed that albuterolevoked Forced Expiratory Volume in 1 second (FEV1) was higher and the response was more rapid in Arg-16
homozygotes compared with carriers of the Gly-16 variant (18% increase vs. 4.9% increase, P < 0.03). [19] Similarly, spirometric assessment of 269 participants in a longitudinal study of asthma indicated that homozygotes for Arg-16 were 5.3 times more likely than Gly-16
homozygotes to respond (>15.3% increase in FEV1) to challenge with 180 mcg albuterol. [17] However, different pharmacogenomic associations were found in Indian and
African-American populations. [20] One study showed that patients with the Arg/Arg genotype had increased peak expiratory flow rates (PEFR) when β-2 agonists were withdrawn as a rescue inhaler. In contrast, patients with the Gly/Gly genotype showed good responses to β-2 agonist therapy, which reversed when it was withdrawn. [21] One clinical trial results have indicated a decreased response to longer-term β-2 agonist treatment among patients with Arg/Arg genotype for residue 16 of the β-2AR as well as increased risk of exacerbations among patients with this genotype, who were treated with a short-acting β-2 agonist. [21, 22] However, another study evaluating the effects of variation in the β-2AR gene on clinical response to salmeterol administered with fluticasone propionate found no variation in response to salmeterol after chronic dosing with an inhaled corticosteroid. [23] Recently, ARG1 is identified as a new gene for acute bronchodilator response to β-2 agonist. [24] Some of the studies assessed the association between β-2AR haplotypes and response, with inconsistent results. Drysdale et al. identified that haplotypes predict albuterol response. [20] Contrary to this, associations between β-2AR haplotype and drug response were not found in other studies. [20] In fact, Silverman and colleagues found an opposite association between albuterol response and haplotypes. [20] To conclude, these data clearly indicate that genotype at the β-2AR can influence the response to a variety of treatment regimes with agents acting at this receptor.
However, results from pharmacogenomic analysis of β-2 agonists have varied between different studies and populations [ Table 2 ]. Therefore, additional researches are needed for confirmation of such studies and for treatment recommendations stratified by genotype.
Glucocorticoids
Although GC are the mainstay of treatment for bronchial asthma, there has been increasing recognition of a group of asthmatic patients who do not appear to benefit from glucocorticoid therapy, i.e., the GC-resistant (GCR) asthmatic.
Corrigan has shown enhanced interleukin-2 (IL-2) and shown that GCR subjects had elevated cell numbers expressing IL-2 and IL-4 before prednisolone treatment as compared to the GCS subjects. In contrast to GCS subjects, prednisolone failed to suppress IL-4 and IL-5 expression in the GCR subjects. Therefore, the airway cells from patients with GCR compared with those from GCS asthma patients have different patterns of cytokine gene expression and distinct responses to GC therapy. [25] Studies have shown that the glucocorticoid receptor (GR) in GCR asthmatics exhibits a lower interaction with activator protein-1 (AP-1), and this effect is accompanied by raised levels of AP-1. and AP-1 activities in the absence of drug. [27] This effect was increased following the addition of dexamethasone [ Table 3 ]. AP-1 and NF-κB repression was also observed following overexpression of a GR ligand-binding mutant in the same cell line. This is in contrast to other studies carried out in different cells, which have shown GR-mediated AP-1 and NF-κB repression to be strictly hormone dependent. [28] These findings suggest that overexpression of the GR in vivo may be a potentially useful approach to gene therapy, especially as a complimentary or alternative treatment for GCR asthmatics.
In addition, it was found that T lymphocytes and monocytes from GCR subjects generate a twofold excess of Fos protein which is secondary to an increase in the c-Fos transcription rate. Thus, excess c-Fos results in perpetuation of AP-1 mediated inflammation and renders the therapeutic effects of GC less effective by sequestration of GR within the nucleus. [29] Many cases of GC resistance may be due to mutations or polymorphisms present in the GR gene (GR/NR3C1). [30] There are two naturally occurring isoforms of the NR3C1:
GR-α (functional) and GR-β (no hormone-binding ability).
Two types of GCR asthma have been identified: type I
(>95% of cases) is cytokine induced and is associated with increased expression of GR-β and type II (<5% of cases) is due to low numbers of GR. Clinically, type I
GCR asthmatic patients present with severe side effects.
Type II GCR asthmatics have a generalized primary cortisol resistance and do not develop steroid-induced side effects. [31] Tantisira and colleagues suggested a relationship between the response to GC and a polymorphism of Corticotrophin Releasing Hormone Receptor 1 (CRHR1)
gene. In the individuals homozygous for the minor allele, the mean percentage change in FEV1 was 13.3% versus 5.5% for those homozygous for the wild-type allele. [32] Same workers had recently demonstrated that a nonsynonymous SNP in the TBX21 (H33Q), the gene coding for transcription factor T-bet (T-box expressed in T cells), is associated with significant improvement in methacholine responsiveness in children with asthma.
However, the minor allele frequency for this SNP was only 4.5%, and there were no homozygotes observed in more than 500 subjects, suggesting that although the effect of such a mutation may be large, it may only affect a small number of individuals. [33] Leukotriene modifiers In 221 patients with mild-to-moderate asthma treated with an ALOX5 inhibitor, ABT-761 (n = 114), or placebo (n = 107), 64 patients (among receiving active treatment) with at least one wild-type allele of [32] CRHR1 variants  increased response to inhaled corticosteroids 1041 mild to moderate asthmatic children Tantisira et al. [33] TXB21 variation  improved methacholine responsivenessthe ALOX5 promoter locus had greater improvement in FEV 1 than the 10 patients without any wild-type alleles (18.8% improvement vs. 1.1% decline, P < 0.0001). [34] In a corroborating study involving the leukotriene receptor antagonist zafirlukast, patients with no wild-type alleles had a 2.3% decrease in FEV 1 , whereas 44 subjects with two wild-type alleles and 19 subjects with at least one wild-type allele had improvements in FEV 1 of 9.1 and 12.8%, respectively. [35] The LTC4 synthase gene polymorphism has been correlated with the response of asthma patients to zafirlukast. Those with variant LTC4 synthase genotype (C/C or C/A genotype, n = 13) had a 9% increase in FEV1, whereas patients with the wild type (A/A genotype, n = 10) had a 12% decrease. [36] This polymorphism also
shows an association with aspirin induced asthma and also contributes to increased LTC4 in the airway. [37] It is also considered as a potential risk factor for adverse reactions to nonsteroidal analgesics in asthma. The mechanism postulated is alteration of expression pattern of the enzyme [ Table 4 ].
Muscarinic receptors
Polymorphic variation within muscarinic M2 and and a common SNP in the 3′ non-coding region (1696T/A), in M2 receptor gene have been identified, which are not relevant functionally. [38] However, no variation has been identified in the M3 coding sequence. In the Japanese population, a degenerate polymorphism in M2 coding region (1050A/G) and a degenerate M3 substitution (261C/T) in M3 coding region were identified. [39] Recently, a variable tandem repeat in the human muscarinic M2 gene promoter has been shown to influence gene transcription in cultured cells. It has been suggested that this variation may be contributory to the development of asthma symptom in patients and inter-individual variability in response to muscarinic antagonists. [40] Phosphodiesterase
The phosphodiesterase E4 (PDE4) represents the predominant cAMP hydrolyzing activity in human airway smooth muscle. [41] Increased activity of PDE4 is expected to decrease β-2 agonist response by degrading β-2AR.
It is also expected to alter the response to theophylline; however, in vivo PD inhibitory action of theophylline is yet to be cleared. [42] It has been suggested that PD genes contain a number of polymorphisms, however, presently no data are available on the mutation screening of PD gene in asthmatics.
Other Genetic Factors
Antiasthma drugs, which are subject to CYP450 metabolism in humans, would be expected to display altered pharmacokinetic profiles in patients carrying the appropriate CYP450 gene variants. Montelukast is sulfoxidated and 21-hydroxylated by the CPY3A4 P450 isoform, while CYP2C9 mediates methyl-hydroxylation of the drug. [43] Salmeterol and budesonide are likewise oxidized by CYP3A, [44] while CYP1A2 is the major enzyme which metabolizes theophylline at therapeutic concentrations. [45] Functional polymorphisms affecting the genes coding for these CYP450 isoforms might [34] ALOX5 variation -increase in FEV1 with ABT-761 221 Moderate asthmatics Sampson et al. [37] LTC4S variation -increase in FEV1 23 Asthmatic patients Anderson et al. [35] LTC4S variation -increased response and FEV1 with zafirlukast that the genetic variation at the CCL11 locus is an important determinant of serum total IgE levels among patients with asthma [46] and it is reasonable to suggest that CCL11 genotype may influence the response to medications that exert their effect via IgE receptors (e.g., Omalizumab). However, studies carried out, to date, have not evaluated this possibility.
Current and Future Perspectives of Pharmacogenomics
Pharmacogenomics enables a more patient-focused prescribing and helps to ensure that patients receive the drugs that would benefit them the most. Pharmacogenomic 
